Silence Therapeutics SLN Growth Metrics (2019-2026)

NASDAQ SLN
$19.77 +0.02 (+0.10%)
As of: Nov 10, 2026 · 1:53 PM EST
Reported Financials

Silence Therapeutics Quarterly Growth Metrics

Periods 14 quarters
Latest Jun 2026

Silence Therapeutics reported asset growth of -35.60% for the quarter ended Jun 2026. These growth metrics cover 14 quarters of results from Dec 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Growth MetricsGrowth Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Growth Ratios
Share-based Compensation (QoQ)Stock Comp. (QoQ) 0.56%-1.79%-2.11%-11.08%-41.10%21.58%-103.39%2,945.35%-46.55%
Share-based Compensation Growth (1y)Stock Comp. Growth (1y) -14.04%-49.65%-37.67%-102.16%-30.88%-37.27%
Revenue (QoQ) -94.90%87.25%1,589.25%-99.44%57.75%-29.02%-78.62%1,141.18%
Revenue Growth (1y) -99.10%-72.00%-89.39%-99.87%197.18%
Return on Sales [ROS] (QoQ)ROS (QoQ) -0.29M0.09M0.20M-2.00M0.93M-0.58M-2.01M3.29M-0.74M
Return on Sales [ROS] Growth (1y)ROS Growth (1y) -2.00M-0.78M-1.45M-3.66M1.63M-0.04M
Return on Equity [ROE] (QoQ)ROE (QoQ) 0.00M0.00M-25.00-0.01M-439.00-210.00
Return on Equity [ROE] Growth (1y)ROE Growth (1y) -0.01M-0.01M-0.01M
Return on Capital Employed [ROCE] (QoQ)ROCE (QoQ) -472.00-581.000.00M308.00-17.00
Return on Capital Employed [ROCE] Growth (1y)ROCE Growth (1y) 0.00M0.00M
Return on Assets [ROA] (QoQ)ROA (QoQ) -827.00378.000.00M283.00674.00
Return on Assets [ROA] Growth (1y)ROA Growth (1y) 0.00M-898.00
Property, Plant & Equipment (Net) (QoQ)PP&E (Net) (QoQ) -6.88%4.84%-6.76%-4.47%-11.70%-5.09%
Property, Plant & Equipment (Net) Growth (5y)PP&E (Net) Growth (5y) 14.58%17.81%0.58%
Property, Plant & Equipment (Net) Growth (3y)PP&E (Net) Growth (3y) 30.93%49.06%14.54%-11.51%-15.85%
Property, Plant & Equipment (Net) Growth (1y)PP&E (Net) Growth (1y) -31.47%91.73%70.82%1.12%-13.00%-21.25%-13.04%-17.54%-25.35%
Operating Margin (QoQ) -0.29M0.09M0.20M-2.00M0.93M-0.58M-2.01M3.29M
Operating Margin Growth (1y) -2.00M-0.78M-1.45M-3.66M1.63M
Operating Income (QoQ)Op. Inc (QoQ) -319.06%-28.26%85.49%-552.78%15.65%-9.52%52.52%-26.29%11.90%
Operating Income Growth (1y)Op. Inc Growth (1y) -409.03%-2.46%12.51%-186.33%44.61%42.14%
Net Margin (QoQ) -0.25M0.01M0.24M-2.01M0.79M-0.10M-2.14M3.11M
Net Margin Growth (1y) -2.01M-0.97M-1.08M-3.47M1.65M
Net Income towards Common Stockholders (QoQ)Net Income (QoQ) -754.46%-79.92%134.61%-331.91%4.12%23.38%43.84%-27.08%17.98%
Net Income towards Common Stockholders Growth (1y)Net Income Growth (1y) -1,134.00%-38.47%41.04%-195.68%47.57%55.15%
Net Income (QoQ) -754.46%-79.92%134.61%-331.91%4.12%23.38%43.84%-27.08%17.98%
Net Income Growth (1y) -1,134.00%-38.47%41.04%-195.68%47.57%55.15%
Net Cash Flow (QoQ)NCF (QoQ) -105.76%-1,209.58%169.11%-247.03%58.81%272.98%-274.92%92.07%1,285.88%
Net Cash Flow Growth (1y)NCF Growth (1y) -176.62%-448.13%172.40%-283.26%90.11%384.62%
Income After Tax (QoQ) -754.46%-79.92%134.61%-331.91%4.12%23.38%43.84%-27.08%17.98%
Income After Tax Growth (1y) -1,134.00%-38.47%41.04%-195.68%47.57%55.15%
Gross Profit (QoQ) -119.98%16.92%1,186.74%-99.62%57.95%-31.65%-76.84%1,768.18%
Gross Profit Growth (1y) -99.32%105.39%104.44%-99.91%367.05%
Gross Margin (QoQ) -0.04M0.02M0.02M0.00M8.00-231.00496.000.00M
Gross Margin Growth (1y) 0.00M0.04M0.02M0.00M0.00M
Free Cash Flow (QoQ)FCF (QoQ) 39.91%-367.26%-7.29%55.30%-77.31%50.03%-58.57%9.81%109.63%
Free Cash Flow Growth (1y)FCF Growth (1y) -34.67%-297.38%57.50%37.19%-26.72%106.88%
FCF Margin (QoQ) -0.06M-0.10M0.16M-0.86M-0.11M0.29M-4.40M4.72M
FCF Margin Growth (1y) -0.86M-0.91M-0.51M-5.08M0.50M
EPS (Diluted) (QoQ) -703.70%-78.66%135.22%-327.12%4.13%23.39%43.84%-27.07%17.98%
EPS (Diluted) Growth (1y) -1,048.66%-37.01%41.25%-193.69%47.58%55.16%
EPS (Basic) (QoQ) -703.70%-78.66%135.22%-327.12%4.13%23.39%43.84%-27.07%17.98%
EPS (Basic) Growth (1y) -1,048.66%-37.01%41.25%-193.69%47.58%55.16%
EBT (QoQ) -844.25%-81.77%135.57%-325.96%4.16%23.36%43.84%-27.08%17.98%
EBT Margin (QoQ) -0.24M0.01M0.24M-2.01M0.79M-0.10M-2.14M3.11M
EBT Margin Growth (1y) -2.01M-0.98M-1.08M-3.47M1.65M
EBT Growth (1y) -1,279.59%-40.03%40.96%-193.22%47.57%55.14%
EBIT (QoQ) -319.06%-28.26%85.49%-552.78%15.65%-9.52%52.52%-26.29%11.90%
EBIT Margin (QoQ) -0.29M0.09M0.20M-2.00M0.93M-0.58M-2.01M3.29M
EBIT Margin Growth (1y) -2.00M-0.78M-1.45M-3.66M1.63M
EBIT Growth (1y) -409.03%-2.46%12.51%-186.33%44.61%42.14%
EBITDA Margin (QoQ) -0.29M0.09M0.20M-1.99M0.93M-0.58M-1.99M3.26M
EBITDA Margin Growth (1y) -1.99M-0.77M-1.44M-3.63M1.62M
Cash from Operations (QoQ)Cash from Ops. (QoQ) 40.84%-373.41%-7.32%55.21%-76.98%49.93%-58.61%9.81%109.63%
Cash from Operations Growth (1y)Cash from Ops. Growth (1y) -34.63%-302.74%57.41%37.05%-26.76%106.90%
Cash from Investing Activities (QoQ)Cash from Investing (QoQ) 99.91%-88,597.67%273.37%-167.12%96.48%3,383.55%-204.00%118.75%549.40%
Cash from Investing Activities Growth (1y)Cash from Investing Growth (1y) 11.07%-3,532.56%234.48%-180.66%122.53%4,257.49%
Cash & Equivalents (QoQ)Cash & Equiv. (QoQ) -46.52%-35.67%96.53%-86.25%-49.84%1,173.71%
Cash & Equivalents Growth (5y)Cash & Equiv. Growth (5y) 20.32%46.92%-21.33%
Cash & Equivalents Growth (3y)Cash & Equiv. Growth (3y) 53.80%55.07%22.51%6.92%-44.53%
Cash & Equivalents Growth (1y)Cash & Equiv. Growth (1y) -35.04%111.12%165.30%-33.42%4.11%76.34%-90.71%-91.28%72.63%
Capital Expenditures (QoQ)Capex (QoQ) -24.71%-3.13%-93.55%1,100.00%-93.75%
Capital Expenditures Growth (1y)Capex Growth (1y) -43.53%-95.31%
Assets (QoQ) -8.56%-10.83%-11.16%-10.46%-12.42%-7.57%
Assets Growth (1y) 69.64%-35.13%-37.87%-35.60%

Silence Therapeutics Growth Metrics API

Pull Silence Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=SLN&statement=Growth&frequency=Quarter&period=all&api_key=YOUR_API_KEY